Drug profile · INN
daprodustat
JESDUVROQ
daprodustat (JESDUVROQ) is a hypoxia-inducible factor prolyl hydroxylase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — daprodustat
- US status
- approved
- Class
- Blood and blood forming organs (B03)
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
daprodustat (JESDUVROQ) is a hypoxia-inducible factor prolyl hydroxylase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Hypoxia-inducible factor prolyl hydroxylase inhibitor
Primary target: Hypoxia-inducible factor prolyl hydroxylase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | application withdrawn | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is daprodustat?
daprodustat (JESDUVROQ) is a hypoxia-inducible factor prolyl hydroxylase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for daprodustat?
JESDUVROQ is a marketed brand name for daprodustat. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of daprodustat?
daprodustat has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.